2024
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-ControlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agents
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy
1993
Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis
Weiner H, Mackin G, Matsui M, Orav E, Khoury S, Dawson D, Hafler D. Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis. Science 1993, 259: 1321-1324. PMID: 7680493, DOI: 10.1126/science.7680493.Peer-Reviewed Original ResearchConceptsMultiple sclerosisOral tolerizationMyelin antigensAutoimmune diseasesDouble-blind pilot trialRelapsing-remitting multiple sclerosisDouble-blind studyCentral nervous systemMyelin basic proteinMajor exacerbationsDaily capsuleT cellsT lymphocytesPilot trialSide effectsNervous systemControl groupMyelin componentsBovine myelinDiseaseMyelinTolerizationSclerosisAntigenBasic protein
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply